David A. Siegel Ac Immune Sa Transaction History

Two Sigma Advisers, LP

$47 Billion
Q3 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Ac Immune Sa stock. As of the latest transaction made, Two Sigma Advisers, LP holds 20,938 shares of ACIU stock, worth $69,304. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,938

Previous 28,810 27.32%

Holding current value

$69,304

Previous $58,000 8.62%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.99 - $3.04 $15,665 - $23,930	-7,872 Reduced 27.32%	20,938 $63,000
Q2 2025 Aug 14, 2025	BUY	$1.48 - $2.2 $7,696 - $11,440	5,200 Added 22.02%	28,810 $58,000
Q1 2025 May 15, 2025	BUY	$1.87 - $2.98 $19,074 - $30,396	10,200 Added 76.06%	23,610 $44,000
Q4 2024 Feb 14, 2025	BUY	$2.67 - $3.75 $35,804 - $50,287	13,410 New	13,410 $36,000
Q2 2022 Aug 15, 2022	SELL	$2.35 - $4.47 $55,563 - $105,688	-23,644 Closed	0 $0

Q1 2022 May 16, 2022	SELL	$3.5 - $5.16 $245,700 - $362,232	-70,200 Reduced 74.8%	23,644 $95,000
Q4 2021 Feb 14, 2022	SELL	$4.83 - $7.56 $91,287 - $142,884	-18,900 Reduced 16.76%	93,844 $465,000
Q3 2021 Nov 15, 2021	BUY	$6.2 - $8.34 $133,920 - $180,144	21,600 Added 23.7%	112,744 $757,000
Q2 2021 Aug 16, 2021	BUY	$6.04 - $8.37 $460,248 - $637,793	76,200 Added 509.9%	91,144 $723,000
Q1 2021 May 17, 2021	BUY	$5.32 - $8.96 $79,502 - $133,898	14,944 New	14,944 $114,000
Q3 2020 Nov 16, 2020	SELL	$4.78 - $9.06 $71,432 - $135,392	-14,944 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.57 - $8.3 $21,313 - $26,925	3,244 Added 27.73%	14,944 $101,000
Q1 2020 May 15, 2020	BUY	$4.24 - $9.89 $49,608 - $115,713	11,700 New	11,700 $81,000

Others Institutions Holding ACIU

# of Institutions

Shares Held

26.8M

Call Options Held

94.9K

Put Options Held

22.5K

View Full List

About AC Immune SA

Ticker ACIU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,413,504
Market Cap $276M
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...

More about ACIU

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account